TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04221750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle therapy
Description: Weight management program, in which participants are prescribed a balanced diet that provides and energy deficit of 500 to 750 kcal per day to induced \~10% weight loss plus Supervised combined aerobic and resistance exercise training three times weekly

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle therapy
Description: Weight management program, in which participants are prescribed a balanced diet that provides and energy deficit of 500 to 750 kcal per day to induced \~10% weight loss plus Supervised combined aerobic and resistance exercise training three times weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride
Description: Given orally starting at 500 mg (one tablet) taken orally once a day with meals. After a week, the dose of metformin will be increased to 1000 mg (two tablets) daily. After another week, the dose of metformin will be increased to 1500 mg (three tablets) daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Given orally starting at 500 mg (one tablet) taken orally once a day with meals. After a week, the dose of metformin will be increased to 1000 mg (two tablets) daily. After another week, the dose of metformin will be increased to 1500 mg (three tablets) daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given orally starting at 500 mg (one tablet) taken orally once a day with meals. After a week, the dose of placebo will be increased to 1000 mg (two tablets) daily. After another week, the dose of placebo will be increased to 1500 mg (three tablets) daily.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Lifestyle
Description: Group educational sessions that focus on healthy diet, exercise, and social support once a month
Study: NCT05676944

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Labyrinth Devices MVI™ Multichannel Vestibular Implant System
Description: Unilateral implantation of a Labyrinth Devices MVI™ Multichannel Vestibular Implant System receiver/stimulator including insertion of electrode arrays in the semicircular canal ampullae of the inner ear, followed by motion-modulated prosthetic electrical stimulation.
Study: NCT05129969

Intervention type: OTHER
Intervention: Physician's choice according to patient's needs.
Description: Routine care as per site standard.

Intervention type: OTHER
Intervention: Physician's choice according to patient's needs.
Description: Routine care as per site standard.
Study: NCT06332352

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: Intra-articular hip injection of PRP, Blood Collection 45mL, Processed Neutrophil-Poor PRP, 1 injection to one hip joint.
Study: NCT06636734

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT04647786

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype medical device (SEA CtV)
Description: A prototype device that delivers a controlled flow of gas to the upper airways via the subglottic suction port of an established tracheostomy tube. Gas flow may be timed, warmed and/or humidified.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype medical device (SEA CtV)
Description: A prototype device that delivers a controlled flow of gas to the upper airways via the subglottic suction port of an established tracheostomy tube. Gas flow may be timed, warmed and/or humidified.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype medical device (SEA CtV)
Description: A prototype device that delivers a controlled flow of gas to the upper airways via the subglottic suction port of an established tracheostomy tube. Gas flow may be timed, warmed and/or humidified.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype medical device (SEA CtV)
Description: A prototype device that delivers a controlled flow of gas to the upper airways via the subglottic suction port of an established tracheostomy tube. Gas flow may be timed, warmed and/or humidified.
Study: NCT05329766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quemliclustat
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Administered as specified in the treatment arm
Study: NCT06425211

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic exercises
Description: Recognition of the pelvic area, respiratory management, lumbo-pelvic mobilization, discrimination of abdomino-pelvic contraction and myofascial release techniques.
Study: NCT05329766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered as specified in the treatment arm
Study: NCT05257083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab
Description: Daratumumab will be administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered SC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib will be administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered SC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered orally.
Study: NCT06425211

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic exercises
Description: Recognition of the pelvic area, respiratory management, lumbo-pelvic mobilization, discrimination of abdomino-pelvic contraction and myofascial release techniques.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic exercises
Description: Recognition of the pelvic area, respiratory management, lumbo-pelvic mobilization, discrimination of abdomino-pelvic contraction and myofascial release techniques.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perineal electromyographic biofeedback
Description: Free muscle work and gross motor coordination:

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perineal electromyographic biofeedback
Description: Free muscle work and gross motor coordination:

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perineal electromyographic biofeedback
Description: Free muscle work and gross motor coordination:

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: Muscular proprioceptive work: 50 Hz 300 µs

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: Muscular proprioceptive work: 50 Hz 300 µs

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: Muscular proprioceptive work: 50 Hz 300 µs
Study: NCT05447455

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus Abdominis Plane Block
Description: A 22-gauge spinal needle was introduced from medial to lateral in-plane to the ultrasound probe, and 20 mL of bupivacaine 0.25% was injected under visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic wound infiltration
Description: 40 mL of bupivacaine 0.25% was injected subcutaneously into the surgical wound (20 mL on each of the upper and lower sides) by the obstetrician before skin closure
Study: NCT05257083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilta-cel
Description: Cilta-cel will be administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered intravenously.
Study: NCT01540747

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myo-inositol + folic acid + melatonin
Description: Myo-inositol (2000mg)+ folic acid (200 mcg)+ melatonin(3 mg)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Myo-inositol + folic acid
Description: Myo-inositol (2000mg) + folic acid (200 mcg)
Study: NCT05518955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality and eye mask
Description: Participates will receive a virtual reality program 30 min before their sleep and combine with the sleep routine program for consecutive 2 nights in the ICU.
Study: NCT05028816

Intervention type: DEVICE
Group type: OTHER
Intervention: Side 1: Final layer closure with force modulating tissue bridges (FMTB)
Description: Brijjit is a non-invasive wound closure device that reduces tension on scars and aids improving scar appearance.

Intervention type: OTHER
Group type: OTHER
Intervention: Side 1: Final layer dermal closure with poliglecaprone 25 suture
Description: Current method of wound closure

Intervention type: DEVICE
Group type: OTHER
Intervention: Side 2: Final layer closure with force modulating tissue bridges (FMTB)
Description: Brijjit is a non-invasive wound closure device that reduces tension on scars and aids improving scar appearance.

Intervention type: OTHER
Group type: OTHER
Intervention: Side 2: Final layer dermal closure with poliglecaprone 25 suture
Description: Current method of wound closure
Study: NCT06062095

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AI-powered computer-aided diagnosis (CADx)
Description: Real time AI will be used to diagnosis polyps found during colonoscopy.
Study: NCT05240807

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Photon counting computed tomography (PC-CT)
Description: Cardiac CT imaging will be performed using a newly developed CT scanner that uses photon-counting detectors and the results compared to those from conventional CT, MRI, or nuclear medicine imaging systems

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Photon counting computed tomography (PC-CT)
Description: Cardiac CT imaging will be performed using a newly developed CT scanner that uses photon-counting detectors and the results compared to those from conventional CT, MRI, or nuclear medicine imaging systems
Study: NCT04947410

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP or nasal dilators
Description: CPAP = active comparator nasal dilators = placebo comparator

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CPAP or nasal dilators
Description: CPAP = active comparator nasal dilators = placebo comparator
Study: NCT06490081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: During concurrent chemoradiotherapy in limited-stage small cell lung cancer, Trilaciclib is administered prophylactically before the first cycle of chemotherapy
Study: NCT04972422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c3
Description: ZN-c3 is a study drug
Study: NCT05491681

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intravenous delivery of allogeneic bone marrow-derived MSCs
Description: MSCs

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intravenous delivery of allogeneic bone marrow-derived MSCs
Description: MSCs

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intravenous delivery of allogeneic bone marrow-derived MSCs
Description: MSCs
Study: NCT04966650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5-mins brief nursing advice incorporating with Social Cognitive Theory (SCT)
Description: The protocol is about the relationship between exercise and mental health, the advantages of increase physical activity and regular exercise, and highlight the consequence if not deal with the depressive symptoms.
Study: NCT06199544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Comparing the effect of drugs on symptoms of PCOS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Comparing the effect of drugs on symptoms of PCOS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Comparing the effect of drugs on symptoms of PCOS
Study: NCT05725824

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTE hearing aid with compatible earmolds
Description: Hearing aids will be fit with three different types of customized earmolds. They will only wear each earmold group for the duration of the test (total = \~2.5 hours). Hearing aids will be programmed to a simulated mild, flat, sensorineural hearing loss of 30 dB HL from 250-8000Hz. A short washout period will follow completion of testing with ear earmold group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTE hearing aid with compatible earmolds
Description: Hearing aids will be fit with three different types of customized earmolds. They will only wear each earmold group for the duration of the test (total = \~2.5 hours). Hearing aids will be programmed to a simulated mild, flat, sensorineural hearing loss of 30 dB HL from 250-8000Hz. A short washout period will follow completion of testing with ear earmold group.
Study: NCT05257083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered intravenously.
Study: NCT05231278

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nCLE aided RANB biospy
Description: nCLE aided RANB biopsy procedure using the Monarch® robotic-assisted navigational bronchoscopy platform and Cellvizio® I.V.E. system with AQ-Flex™ 19 Confocal Miniprobe™ used in combination with Fluorescein.
Study: NCT06582199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Plasma, DNA, RNA and PBMC Sampling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological battery tests
Description: * Short term memory: Digit span (forward and backward)~* Long term memory: Free and Cued selective reminding Test~* Language and semantic Memory : Verbal Fluency (Category and Litteral), Image Naming (DO 40)~* Praxis~* Visuo Spatial abilities: Rey-Osterrieth Complex Figure Test~* Attention and executive functions: Trail Making Test (TMT) Part A and B, Frontal Assessment Battery (FAB)~* Autonomy in daily life activities : Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL), Instrumental Activities of Daily Living (IADL)~* Mood and anxiety: Hospital Anxiety and Depression Scale (HADS)~* Cognitive reserve : Cognitive Reserve Index questionnaire (CRIq)
Study: NCT06311253

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Emoform Glic Toothpaste
Description: Daily use of Emoform Glic toothpaste twice a day during home oral hygiene

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emoform Glic Toothpaste
Description: Daily use of Emoform Glic toothpaste twice a day during home oral hygiene

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emoform Glic Mouthwash
Description: Daily use of Emoform Glic mouthwash twice a day during home oral hygiene
Study: NCT05079568

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculus Go VR headset
Description: Virtual reality programs consisting of interactive games, meditation and deep breathing exercises, and passive virtual reality experiences designed to facilitate relaxation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Oculus Go VR headset
Description: Virtual reality program with two-dimensional nature video
Study: NCT06418529

Intervention type: DRUG
Intervention: tofacitinib
Description: New index treatment of tofacitinib

Intervention type: DRUG
Intervention: tumor necrosis factor inhibitors (TNFi)
Description: New index treatment of TNFi

Intervention type: DRUG
Intervention: abatacept
Description: New index treatment of abatacept

Intervention type: DRUG
Intervention: tocilizumab or sarilumab
Description: New index treatment of tocilizumab or sarilumab
Study: NCT05524883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DYNE-251
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DYNE-251
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered by IV infusion
Study: NCT04621266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Home-based peer support
Description: Online Home-based peer support will be provided to support participants' breastfeeding. There will be a minimum of 2 and maximum of 3 home visits between trained peer counsellors and participants. Each session will last approximately 30 minutes.
Study: NCT06456853

Intervention type: OTHER
Intervention: Pain assesment
Description: We will ask patients about their pain and will try to asses their pain scores. Then we will ask them to which methot is more suitable for assesment.

Intervention type: OTHER
Intervention: Pain assesment
Description: We will ask patients about their pain and will try to asses their pain scores. Then we will ask them to which methot is more suitable for assesment.
Study: NCT06268574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVU120
Description: RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19
Study: NCT05772169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone 300 MG [Korlym]
Description: Mifepristone tablets for once daily oral dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for mifepristone
Description: Placebo tablets for once daily oral dosing
Study: NCT05027958

Intervention type: DRUG
Group type: OTHER
Intervention: Tuberculin Purified Protein Derivative
Description: PPD administered through the airways to elicit the development of alveolar inflammation challenge dose of 0.5 TU

Intervention type: DRUG
Group type: OTHER
Intervention: Tuberculin Purified Protein Derivative
Description: PPD administered through the airways to elicit the development of alveolar inflammation challenge dose of 0.5 TU
Study: NCT06249152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS-111, 0.015%
Description: QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS-111, 0.030%
Description: QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS-111, 0.075%
Description: QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: QLS-111 vehicle ophthalmic solution
Description: Vehicle drops applied QPM for 14 days the BID for 14 days.
Study: NCT06033547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir Formulation F
Description: Cabotegravir Formulation F will be administered
Study: NCT05725824

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BTE hearing aid with compatible earmolds
Description: Hearing aids will be fit with three different types of customized earmolds. They will only wear each earmold group for the duration of the test (total = \~2.5 hours). Hearing aids will be programmed to a simulated mild, flat, sensorineural hearing loss of 30 dB HL from 250-8000Hz. A short washout period will follow completion of testing with ear earmold group.